Clareo Health | Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology
Enumeration of Circulating Tumour Cells (CTCs) in Patients With Advanced Solid Malignancy Using Complementary Metal Oxide Semiconductor (CMOS) Technology
1. Patients with a diagnosis of either metastatic NSCLC or metastatic CRC are eligible.
2. Patients should be due to undergo palliative chemotherapy as part of their standard clinical care.
3. Patients must be able to receive and understand verbal and written information regarding the study and give written, informed consent.
You may not be if
1. Persons under 18 years of age.
2. Conditions in which research blood sampling may increase risk of complications for the patient and/or the investigators. For example, uncontrolled bleeding, patients with a known blood-borne viral infection (eg. hepatitis B or C, HIV) or poor venous access.
3. Other persons in whom clinical judgement by the investigator concluded that the patient should not participate in the study. For example, anticipated poor compliance to attend for follow-up.
